Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06922539RecruitingPhase 1
Experimental drug ST-001 nanoFenretinide for small cell lung cancer
This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.
Los Angeles, CaliforniaAges 18 years+ - NCT06883526RecruitingPhase 1/Phase 2
ZG005 plus gecacitinib for lymphoma that has returned or not responded
This trial tests a combination of two drugs, ZG005 and gecacitinib, for people with lymphoma that has come back or hasn't gotten better with prior treatment. The goal is to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06803875RecruitingPhase 1/Phase 2
CAR T cells for relapsed high-risk neuroblastoma
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
Boston, MassachusettsAges 1–29 - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04961515RecruitingPhase 2
Orelabrutinib with immunotherapy and temozolomide for CNS lymphoma
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hangzhou, ZhejiangAges 18–75 - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06612645RecruitingPhase 1
CAR T cell therapy for children with solid tumors that returned
This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.
Bangkok, PathumwanAges 1–25 - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT06499025Enrolling by invitationEarly Phase 1
T-cell therapy for a type of AML with the AML1-ETO gene
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT06356571RecruitingPhase 2
Isatuximab with carfilzomib and dexamethasone for multiple myeloma
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
Phoenix, ArizonaAges 18 years+ - NCT06345027RecruitingPhase 1
CAR T cell therapy targeting CD70 for leukemia
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Houston, TexasAges Up to 75 years - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT06066203RecruitingPhase 1/Phase 2
Study of GNC-035 for lymphoma that returned or didn't respond to treatment
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–75 - NCT05950802RecruitingPhase 1
Improving how CAR T cells are timed for lymphoma outcomes
This Phase 1 trial tests a method to better time “cell therapy” (CAR T) called Yescarta in people with relapsed or refractory large B-cell lymphoma. The goal is to improve outcomes by optimizing how the body is prepared before CAR T treatment.
Toronto, OntarioAges 18 years+ - NCT02863692Recruiting
Registry study for chronic lymphocytic leukemia patients
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
Dresden, SaxonyAges 18 years+ - NCT05623982RecruitingPhase 1/Phase 2
Study drug for lymphoma that has returned or did not respond
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
Beijing, Beijing MunicipalityAges 18–75 - NCT05580601RecruitingPhase 1/Phase 2
Immunotherapy trial for children with relapsed or stubborn AML
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
Cincinnati, OhioAges 2 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT04881240RecruitingPhase 1
Donor T-cell therapy for CD19-positive leukemia in young patients
This study tests a new treatment using donor immune cells (T-cells) that target a protein called CD19 on leukemia cells. It is for children and young adults with CD19-positive leukemia that has come back or not responded to standard treatments.
Memphis, TennesseeAges Up to 21 years
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.